Acelyrin (SLRN) Adopts Limited-Duration Stockholder Rights Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
March 13, 2025 7:00 AM EDTLOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners continued rapid accumulation of 8.8% of ACELYRINS outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan (Rights Plan).
The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value.
Pursuant to the Rights Plan, the Company is... More
